On September 22, Abivax S.A. fell 5.47% in regular trading, trading near $97.985 per share with turnover of approximately $28.76 million. The decline was triggered by a significant H1 earnings miss and subsequent analyst downgrades.

Abivax S.A. reported H1 losses of $(2.43) per share, missing the consensus estimate of $(1.08) by 125%, representing a 65.31% increase in losses compared with $(1.47) per share in the year-ago period. While revenue of $2.959 million beat the $1.860 million estimate, the widening loss weighed heavily on sentiment. In response, Wedbush cut its price target to $118 from $160 while maintaining a Neutral rating, and Truist lowered its target to $151. The average analyst price target now stands at $164.20.

Separately, Abivax S.A. announced a chief medical officer transition, with Chris Rabbat set to succeed Fabio Cataldi in Q4. The company continues advancing its NDA submission for obefazimod in ulcerative colitis, targeted for year-end, and closed a $920 million ADS offering in July to fund operations into Q4 of 2029.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)